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Abstract text 
The coatings application onto medical devices has experienced a continuous growth in the last 
few years. Medical device coating market is expected to grow at a CAGR of 5.16% to reach 
USD 10 million by 2023 due to the increasing geriatric population and the growing demand 
for continuous innovation. Layer-by-Layer (LbL) assembly represents a versatile method to 
modify the surface properties, in order to control cell interaction and thus enhance biological 
functions. Furthermore, LbL is environmentally friendly, able to coat all types of surfaces 
with the creation of homogenous film and to include and control the release of 
biomolecules/drugs. This feature review provides a critical overview on recent progresses in 
functionalizing materials by LbL assembly for bone regeneration and disorder treatment. An 
overview of emerging and visionary opportunities on LbL technologies and further 
combination with other existing methods used in biomedical field, are also discussed to 
evidence the new challenges and potential developments in bone regenerative medicine. 
1. Introduction 
Layer-by-Layer technique 
Blodgett transferred insoluble monolayers from water surface to solid substrates [1]. 
Langmuir-Blodgett films and the build-up of multilayers by alternative adsorption of anionic 
and cationic polyelectrolytes have been adapted into different LbL methods to generate 
functional material and surface for a wide range of applications in different fields. Due to the 
limited availability of analysis technology and eventually awareness of those ones existing 
within the different fields, the evolution of LbL was slow until its (re)-discovery in the 1990s, 
*Revised Manuscript
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when a full characterisation of the LbL thin multilayers and the use of robots and automated 
dipping technologies fastened the built-up and subsequent characterization of multilayers [2, 3]. 
Traditional LbL assembly consists in the adsorption of positive and negative charged 
polyelectrolytes onto a substrate, which has been requested by different fields where 
assemblies are built one layer at time [4]. Furthermore, LbL assembly exploits diffusion-driven 
kinetics by immersing the substrates into material solution(s) to facilitate the molecules 
adsorption onto the substrates, followed by washing/rinsing steps to remove not adsorbed 
material. Since these steps are tedious and time-consuming, technological efforts have been 
centered in order to overcome these practical issues by reducing the deposition time and 
assembly while controlling the coating surface properties [5]. These resulted in the use of 
automated machines with driving assembly technologies that enable a structured layering of 
materials rather than the solely and random molecules diffusion [6]. Traditional LbL assembly 
approach was adapted into unconventional and quasi-LbL approaches, in which the 
development of films is centered on the integration of different interdisciplinary fields for 
controlling the assembly at larger or smaller scale rather than looking to get deeper 
understanding of the film formation and properties at molecular level [2]. However, in this 
feature review, we will focus on those LbL assembly techniques that build sequentially coated 
surfaces or structures at nanoscale (below 1µm) applied to regenerate or treat disorders 
concerning bone tissue. Among the different methods, the traditional immersive LbL is the 
most widely used assembly-based technology due to the simplicity of the dipping process for 
coating almost any geometry or size substrate, which makes this approach easily accessible. 
However, the possibility that unbound molecule residues, not fully removed during the 
washing steps subsequent to each deposition, limit its efficiency for practical and scale-up 
applications [3]. Improvements of this technique to speed up the assembly process include the 
promotion of faster kinetics by e.g. dewetting the deposited nanolayers [7] [8]. In the last 
decades, the use of alternative techniques such as spray and spin-assisted LbL, 
electromagnetic and fluidic has gained a lot of importance (Figure 1), particularly in the 
biomedical field. Moreover, LbL assembly has evolved from an academic curiosity into an 
opening technology to change industry (e.g. 3M applies LbL assembly as platform technology 
in electronics, energy and healthcare) [9]. Particularly, in the last five years, research on LbL 
assemblies applied to bone tissue field has gained importance by nearly doubling the number 
of publications. By a simple key-word search on ISI Web of Knowledge database of topic 
-by- -by- -by-
-by- ppreciate that 
the number of publications (Figure 2) on LbL applied to bone regeneration and drug delivery 
is higher (since 2012, increased about 2.3 times) when compared to publications which 
studies LbL effects on bone at nanoscale (x 1.9). However, the first studies on material 
coatings by LbL for bone applications at nanoscale are dated back to the beginning of the new 
century [10, 11]. 
Bone disorders are ascribed to both traumatic and pathological events. To date, the main 
issues associated to bone trauma have to address low osteointegration of synthetic devices and 
poor bone regeneration in case of large bone defects. Bone is a complex and highly dynamic 
tissues composed by many actors which have to be orchestrated by a multifactorial 
methodology in order to achieve the ambitious goal of bone re-growth. LbL offers the unique 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
3 
 
opportunity to impart chemical, physical, biochemical, morphological and topographic 
features in a singular treatment as the versatility of the LbL technology allows to create a 
nanostructured surface morphology loading chemical and biochemical cues. 
In this feature review, we propose an overview on the recent applications of LbL assembly for 
the functionalization at the nanoscale of bone-intended medical devices, describing in the last 
section a visionary perspective of a translational scale-up of this LbL technology for future 
research in the bone field. 
2. Change in topography for enhancing bone healing and regeneration 
Surface topography within few nanometers has been found to trigger specific responses in 
biological systems[12] [13] [14] [15] [16]. The majority of reported research on LbL assembly for 
bone tissue applications relates to the influence of multilayers made of natural polymers onto 
either polymeric or metal substrates on stem cells behaviour and osteogenesis. 
The nature and organisation of the biomolecules or polyelectrolytes (i.e. chemical strucuture 
and molecular lenght of the deposited biomolecules) during the LbL assembly plays a key 
role in the topography and surface properties of the biomaterial, including surface wettability, 
roughness, etc[17, 18] . Surface wettability tends to increase when incorporating hydrophilic 
polyelectrolytes, such as collagen, gelatin (GEL), chitosan (CHI), chondroitin sulfate (CS), 
hyaluronic acid (HA), for promoting ECM biomolecules absorption such as fibronectin, 
which can determine the initial cell attachment of osteoblasts[19]. In general, multilayered 
films made from highly hydrated polyelectrolytes yield very soft and gel-like films, which do 
not favor cells adhesion[17]. In order to modulate the mechanical properties of polylectrolytes 
multilayered (PEM) films, different strategies have been applied, and the most common ones 
include: a) ionic crosslinking by changing pH and ionic strenght [20], chemical by 
incorporating crosslinkers (natural such as genipin or sinthetic like EDC), thiol or disulfide 
groups, photo-crosslinking, and physical through the incorporation of nanoparticles[17]. On 
this regard, by modifying the stiffness of the multilayerd films, cells response can varies to 
the rigidity of the underlying matrix as they exert forces on it, facilitating or preventing their 
migration, adhesion and spreading. 
PEM films can grow either linearly or exponentially at different conditions. Their thickness is 
mostly related to the ability of the polyelectrolyte to up-take water, to the charge density and 
the affinity between pairs of polyelectrolyte with opposite charge [17]. Liu et al found in a 
recent work, that after depositing 6 layers, the thickness of the multilayers changed depending 
GEL/CS, 
films[21]. These results suggest that molecules such as CHI, CS and HA promote thicker films 
when compared to GEL biomolecules. Polysaccharides rich in intra-molecules hydrogen 
bonds, such as chitosan, are rigid molecules with high intrinsic stiffness due to the high 
molecular size and conformation that do not chance significantly during the drying steps of 
the layer-by-layer [21, 22]. However, biomolecules such as gelatin, are flexible due to the low 
molecular weight product of collagen degradation, consequently the molecular conformation 
can change significantly during the drying/wetting steps[23]. Thus, the film thickness may 
increase either linearly or exponentially with the deposited layers depending on the polymer 
conformation and the charge density. Surface charge density can affect polyelectrolytes 
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adsorption such as proteins (depending on the pI, isoelectric point) during the wet steps, and 
ultimately cell response[17]. The typical negatively charged functional groups of natural 
polyelectrolytes (proteins, polysaccharides, etc) includes carboxylic acid and sulfates; and as 
positively charged groups the most common are amines. 
The use of specific biomolecules such as proteins, charged-polysaccharides (i.e. sulfated 
molecules) or GF within the nanocoating can instruct and orchestrate the cell behavior by 
either the surface chemical or mechanical properties, including stiffness and 
topography.Collagen is the main structural protein in bone, its molecules are high molecular size 
and conformation. Although, collagen type-I in acetic acid solution is mainly in the form of 
monomers, it has the ability to assemble into fibrils structures of 50 nm in diameter and several 
micrometers in length at physiological conditions[24]. The collagen-polyelectrolytes build-up into 
films and their thickness follow a linear growth regime with the successive layer depositions, 
leading to uniform and dense fiber network[25] [26] [27]. The dimensions of collagen fiber are usually 
between 150-300nm, this surface topography is not commonly observed for other polylectrolytes 
or proteins, which typically form aggregates with diameters ranged between 50-60nm[26]. 
Moreover, molecules suc
found to promote the assembling and formation of collagen fibers[28]. Particularly, sulfated GAGs 
such as CS , heparin (Hep), heparin sulfate have high affinity to growth factors (GFs) due to sulfate 
groups, these interfere with GFs that participate in the regulation of osteoblastic lineage (such as 
bFGF, TGF- -2 and 3, IGF-II) [18]. 
Other physico-chemical properties, such as polyelectrolyte concentration and charge density, 
can affect the final properties of the assembled multilayers. The pH and use of salts within the 
wetting steps have been shown to change frequency and dissipation energy shifts during the 
QCM monitoring of multilayers deposition[18]. The presence of high salt concentrations (i.e. NaCl 
in the deposition of chitosan and carrageenan) leads to more rigid films as the small ions promote a 
charge shielding effect over the charged groups of the polyelectrolytes, reducing the charge density 
and the amount of material to be deposited [18]. Moreover, the variation of pH can impact also the 
polymer conformation as it is expected to affect the charge density. Consequently, as mentioned 
previously, the film thickness may increase either linearly or exponentially with the deposited 
layers depending on pH variations and salt concentration [17]. 
Moreover, LbL technique is quite versatile as it allows to use these natural polyelectrolytes to 
module mesenchymal stem cells (MSCs) behaviour. For instance, the LbL self-assembly of 
collagen/heparin multilayers have been effectively built up on poly (l-lactic acid) (PLLA) 
films to assess the combined effect of heparin on type I collagen (Col I) hierarchical 
organization on MSCs response. The presence of different Hep/Col I bilayers deposited 
electrostatically on polymeric substrates provides an osteoinductive and osteoconductive 
environment for MSCs at long term by promoting cellular differentiation and bone formation 
[27, 29]. Similarly, the effect of LbL coating of Col I and hyaluronic acid as natural 
polyelctrolytes onto PLLA films on bone cells was evaluated. The presence of Col I as 
terminating layer proved an ehanced cytocompatibility of the PLLA films, improving the cell 
affinity and proliferation , directing the osteoblast organisation by contact guidance with the 
aligned fibril network [30]. Another study on the effect of LbL assembly of different 
combinations of natural polyelectrolytes on MSCs behaviour was recently published. This 
study found that surface topography, specifically a honeycomb-like porous structure as well 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
5 
 
as assembled bioactive molecules play significant roles on the adhesion and proliferation of 
MSCs [21]. Also, the nature of the assembled molecules affects significantly the spatial 
distribution of cells; particularly, the presence of GEL facilitated the cells to remain on the 
substrate surface rather than being confined within the pores. 
In order to mimic the in vivo physiological microenvironment, scientists are also assessing the 
use of the LbL self-assembly method on functionalizing 3D porous scaffold surfaces. He et al, 
-drying technique, and subsequently functionalized it 
through the deposition of cellulose nanowhiskers and chitosan multilayers. The final construct, 
based on a total of 108 self-assembled layers (Figure 3), exhibited improved mechanical 
properties, enhanced osteoblast proliferation and higher levels of biomineralization-relevant 
alkaline phosphatase activity in comparison to the untreated porous scaffolds [31]. Moreover, 
the polyelectrolytes combination based on chitosan/gelatin has lately been investigated to 
further regulate the cell attachment and proliferation of a hydrogel-based scaffold. The 
alginate-derived scaffold was fabricated via internal gelation and subsequently functionalized 
via immersive LbL electrostatic assembly. The resulting composite scaffold showed a better 
3D architecture, along with improved mechanical properties and enhanced ability of 
attachment, proliferation and differentiation of osteoblastic MC3T3-E1 cells [32].  
Furthermore, the use of natural polymers, as multilayer films, has also been greatly 
investigated for the coating of metal and metal-alloy bone implants to improve their bioinert 
behaviour. Recently, Wang et al investigated the effect of alginate/chitosan LbL coating on 
titanium substrates via electrodeposition. In this case, the applied voltage, the deposition time, 
and the concentration of the polyelectrolytes greatly influenced the thickness of the deposited 
layers. Moreover, the in vitro cytocompatibility tests exhibited good cell viability and 
proliferation, with a better cell morphology when the alginate was the outermost layer [33]. 
Beyond the use of natural polymers and since their first introduction in 2002, synthetic 
polycations (such as poly(ethylene imine) (PEI), poly(allylamine hydrochloride) (PAH), and 
poly(L-lysine) (PLL), and polyanions, including poly(sodium 4-styrenesulfonate) (PSS) and 
poly(L-glutamic acid) (PGMA)) are still widely used in pairs or combination with natural 
macromolecules for the production of multilayer films to modify the surface of bone tissue 
engineered structures [11]. Between the advantages of using synthetic polyelectrolytes, their 
chemical stability favors the stability of the topographical cues within the nanostructured 
coating [34]. The biocompatible properties of PSS in combination with chitosan as multilayers 
was been found to improve the biocompatibility of titanium thin films. The multilayer-based 
structures were stable when immerse for more than 3 week in Phosphate Buffered Saline 
(PBS), and the in vitro tests demonstrated a superior osteoblast adhesion and proliferation on 
the PSS/CHI coated films in comparison to the untreated substrates used as control [35]. 
Similar results were evidenced when applying the same combination of polyelectrolytes 
(CHI/PSS) on a polymeric substrate. Particularly, the proliferation and differentiation of 
osteoblast cells was greater on LbL-modified poly-DL-lactic acid (PDLLA) films rather than 
the native substrates [36]. 
Additionally, the combination of electrostatically assembled biodegradable synthetic LbL 
coatings were investigated on AZ31 magnesium alloys. These coatings provided enhanced 
biocompatibility, adhesion and proliferation of both pre-osteoblast MC3T3 cells and hMSCs, 
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in comparison to the uncoated alloy. The development of such surface treatment could be 
used to improve cellular integration for this kind of implants with the native bone tissue [37]. 
More recently, the osteointegration-derived ability of the well-established PSS/PAH 
multilayer has been further assessed using an osteoporotic rabbit model. The in vivo outcomes 
showed that bio-active PEEK with 20 PAH/PSS multilayers significantly improved bone 
mineralization in comparison to the untreated PEEK at the interface bone implant as well as 
within the surrounding tissue. Similarly, no significant difference on microstructure property 
with respect to the native PEEK was reported by increasing the number of nanolayers from 5 
to 10. However, as the number of layers increased from 10 to 20, island-like clusters appeared 
on the surface (Figure 4), followed by a markedly superior proliferation rate of bone marrow 
stromal cells (BMSCs). These results supported the hypothesis for which surface topography 
plays a pivotal role in regulating bio-function of BMSCs [38]. 
 
3. Influence of biomolecules release from LbL nanocoating 
It is well established that the surface-biological environment interactions are essential to drive 
the material performances in vitro and in vivo [39] [40] [41]. LbL allows to combine 3D complex 
substrates, mimicking the biological organ architectures, with a nanostructured multilayer 
functionalised with molecules or fillers to impart bioactive cues to the final device [7]. 
Following the LbL approach, scaffold bulk materials and structures can be engineered 
independently from the surfaces as it can be properly design to steer the cell response towards 
wanted behaviour [42]. In this section, the influence of different biomolecules both organic (e.g. 
growth factors, peptide sequences, drugs, etc.) and inorganic (e.g. hydroxyapatite, 
piezoelectric nanoparticles) from the multilayered LbL coating for bone tissue is summarized, 
in order to give an overview on the materials, procedures and most important findings within 
the last 5 years. 
 
3.1 Incorporation of organic biomolecules 
Bone morphogenetic proteins (BMPs), especially BMP-2 and BMP-7, have been extensively 
investigated for bone healing to enhance tissue regeneration as BMPs are key growth factors 
involved in bone regrowth inducing differentiation of progenitor cells to osteoblasts or bone 
cells [43]. LbL has been recognized as a powerful method to achieve therapeutic efficacy and 
safety of BMP functionalized surfaces as the multilayered structure ensures the maintenance 
of protein stability and prolongs its retention time at the site of action [44]. Microgram-scale 
loading of BMP- -tricalcium 
phosphate ( TCP) 3D-printed scaffold by alternative dipping in chondroitin-sulphate 
and BMP-2 solutions respectively [45]. The multilayered architectures hindered the BMP-2 
burst release (less than 1% after 3 h) and guaranteed a prolonged release reaching a total 
cumulative release of 10 grams after 2 weeks that induced MC3T3 E1S4 pre-osteoblasts 
differentiation in bone cells. 
Recently, unconventional polyelectrolytes able to enhance the protein stability within the 
multilayers have been proposed. The effectiveness of BMP-2 combined with graphene oxide 
has been evaluated by La et al. [46]. Graphene oxide (GO) has emerged as an effective carrier 
for therapeutic proteins delivery, since its hydrophobic domains in the core region and ionized 
groups around the GO edges enhances GO hydrophobic and electrostatic interactions with 
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proteins without affecting protein bioactivity. This feature makes this material a good 
polyelectrolyte for the LbL assembly of positively (GO-NH3+) and negatively charged (GO-
COO-) graphene oxides, and further doping and proteins adsorption. BMP-2 adsorbed into 
GO-based nanomaterials demonstrated an improved osteointegration in titanium implants. 
In the attempt to mimic the physiological multi-cues environment, dual and multiple release 
of proteins have been investigated by combining BMP-2 with vascular endothelial growth 
factor [47] or platelet-derived growth factor-BB [48] in order to induce a simultaneous bone 
tissue growth and angiogenesis. The release of multiple growth factors evidenced that a more 
mature new bone was formed when compared to the single growth factor release [47]. 
Particularly, an increase of the local vascular network combined with a osteoinductive 
environment enhanced the bone remodeling at the injured site [48]. 
Major challenges in the development of multicues nanolayers are the maintenance of protein 
stability, which could be affected by the process steps and the limited number of encapsulated 
proteins due to molecule size. Moreover, several problems are related with the use of proteins, 
such as: dose, cost, folding randomly, vulnerability to degradation, purification and 
immunogenicity [49]. To overcome these issues, the use of short peptides is a feasible approach 
to replicate the binding domains and signaling of the long chain proteins. Recently, Gentile et 
al. proposed the nanoencapsulation of peptides within a multilayered LbL coating. Three 
peptides, KRSR (lysine-arginine-serine-arginine), NSPVNSKIPKACCVPTELSAI and 
FHRRIKA (phenylalanine-histidinearginine-arginine-isoleucine-lysine-alanine), were 
covalently bounded to PAH and then alternated to anionic PSS polyelectrolyte to coat 
composite poly(lactic-co-glycolic acid) (PLGA) /nano-hydroxyapatite electrospun membranes. 
In this work, three bone peptide sequences have been selected for improving specific stages in 
bone regeneration. From literature KRSR sequence, identified in different adhesive proteins 
related with bone (i.e. fibronectin, vitronectin, bone sialoprotein) was found to be suitable for 
enhancing the osteoblast adhesion to scaffold surfaces[50]; NSPVNSKIPKACCVPTELSAI, 
derived from BMP2, showed their potential to induce osteogenesis in vivo [51], while 
FHRRIKA sequence, derived from bone sialoprotein, supported the matrix mineralisation[52]. 
An optimal peptide gradient was designed to induce a osteoinductive in vivo response after 
four-week implantation in non-healing rat calvarial defect model [53]. On this regard, the 
multicues nanolayers were designed to avoid random interactions with proteins by 
introducing targeted peptide-polymer conjugates [54]. 
Different strategies can be used to regulate cell behaviour. For instance, poly(acrylic acid) 
(PAA) was functionalized with alendronate, a bisphosphonate targeting moiety with high 
affinity to bone, to be used as polyanionic compound to coat a solid substrate by 
electrostatically assembly with polycationic PLL (Figure 5) [55]. 
Moreover, RNA interference (RNAi) has been emerged as a powerful method to alter 
biological process by silencing targeted mRNA molecules. Small interfering RNAs (siRNAs) 
have demonstrated enormous potential as therapeutic agents in the treatment of several bone 
disorders, such as osteoporosis and cancer bone metastases  and to enhance 
osteoblastogenesis [56]. Although many studies reported the effectiveness of the siRNA in 
steering biological events, the delivery of siRNAs in living systems still remains a challenge. 
Liposomes and polymeric nanoparticles are the main carriers used for siRNA, however LbL 
holds several advantages both in the processing steps (mild conditions, wide range of 
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materials) and in the tuning of release kinetics. Furthermore, LbL technologies are based on 
self-assembly methodologies, which mimic many biological processes as biomolecules can be 
easily triggered by using mild conditions (pH, temperature) [57]. LbL based siRNA carriers 
have been reported, both for systemic and local delivery [58]. While systemic delivery is a 
versatile and challenging issue, the local delivery approach is easily applied, reduces 
unwanted side effects attributed to systemic delivery and ensures a sustained delivery of 
siRNA to the target tissue [59].  
The osteointegration of titanium surface is a highly investigated topic in orthopaedics and 
dentistry since implant failures are mainly associated to low integration between the implant 
surface and the surrounding bone. LbL was proposed to build up a nanostructured multilayers 
by loading an osteogenic siRNA that targets casein kinase-2 interacting protein-1 (siCkip-1) 
[60]. Chitosan /siRNA nanoparticles were produced and used as polycation while HA acted as 
polyanion. A homogeneous multilayered structure was obtained on titanium surfaces when 8 
bilayers were formed, providing a sustained release of siRNA over approximately one week. 
The effectiveness of the released siRNA was confirmed by the osteogenic differentiation of 
human osteoblast-like cells (MG63). 
Recently, small non-coding RNA (MicroRNAs-miRNAs) have been investigated for their 
ability to coordinate a broad range of biological process. Indeed, miRNAs regulate 
developmental osteogenic signaling pathways, bone homeostasis, bone cells growth and 
differentiation and bone resorption mediated by osteoclast activity in adults playing an 
important role in tissue regeneration and bone disease treatment [61]. Few studies have 
indicated self-assembly technologies as a tool to enhance transfection efficiency and stability 
of miRNAs as naked miRNAs are rapidly degraded in vivo and they are negatively charged 
hindering their uptake by cell membrane (negatively charged) [62]. Recently, osteogenic 
BMSCs differentiation was regulated by targeting mRNA expression through the delivery of 
miRNA (miR-5106) loaded into nanoparticles. MiRNA loading efficacy and delivery kinetics 
was modulated by LbL-based approach, where PEI and liposomes (Lipo) were used as 
polyelectrolytes to coat gold nanoparticles (Au/PEI/Lipo) [63]. Optimized Au/PEI/Lipo-miR-
5106 nanocomplexes upregulated the expression of osteoblast genes enhancing the BMSC 
differentiation into osteoblast-like cells. 
Alternatively to miRNA and siRNA, the delivery of gene encoding osteogenic proteins have 
been proposed to enhance the bone healing process[64]. Non-viral vectors can be obtained 
through layer by layer and the release kinetics can be optimized by modulating the number of 
layers and layers composition. 
3.2 Incorporation of inorganic biomolecules 
Many studies have shown the importance of organic-inorganic biocomposites on the 
performance of bone tissue engineering due to their biomimetic composition, which 
recapitulates physiological bone composition of collagen fibres and hydroxyapatite (HAP) 
crystals [65] (Figure 6A). A mussel-inspired LbL assembly was developed by alternatively 
soaking titanium foil into dopamine buffer solution (pH 8.5) and the 1.5X simulated body 
fluid (SBF) solution [66]. Dopamine is a mussel derived molecule with highly adhesive 
property, which forms a polydopamine layer (PDPOA) in slightly alkaline environments[67]. 
Then, the surface was immersed into SBF solution to achieve HAP precipitation. Murine 
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osteoblastic cell line MC-3T3-E was cultured on 9 bilayer- coated titanium surfaces showing 
good biocompatibility and high cell adherence [68]. 
Another procedure for depositing HAP via LbL has been proposed by Manoukian et al. who 
developed a micro-nanostructured scaffold characterized by a spiral-shaped PLGA porous 
microstructure and a nano-HAP polyelectrolyte-based coating (Figure 6B). Nano-HAP was 
deposited through a LbL process with alternate deposition of cationic chitosan and anionic 
nano-HAP [68]. Unlike traditional HAP coatings, LbL increased the hydroxyapatite 
incorporation creating a highly porous multilayer for calcium and phosphate ions release, a 
fundamental step in reprecipitation of HAP crystals which leads to biomineralization in vivo. 
Indeed, it has been reported that excellent osteoinduction can be achie
calcium/mm2 are released[69]. In order to achieve this therapeutic range, Manoukian et al 
designed a five chitosan/nano-HAP bilayers deposited onto the spiral structure. These 
multilayered structure released 2 that resulted in adhesion, 
proliferation, and osteogenic differentiation of rat bone marrow stromal cells (MSCs). Then, 
scaffold was implanted for ten weeks into a rabbit ulnar bone defect model and in vivo tests 
reported a good bone regeneration, highlighted by the formation of new bone in the central 
section of the scaffold. 
Although the many efforts to impart osteoinductive properties to the scaffold surfaces, one of 
the main causes of implant failure and low bone tissue regrowth is associated to infections. 
LbL offers the opportunity to add antibacterial properties to devices or scaffolds before 
implantation to reduce the risk of infection even in the long-term, as the antibacterial effect 
can be modulated to last after few weeks. Antibacterial composite coatings have been 
assembled using silver nanoparticles as antibacterial agent which, provide antibacterial 
properties by avoiding toxicity to human cells [70]. 
Chitosan silver nitrate complex and heparin were used as polyelectrolytes to produce an 
antibacterial coating on aminolyzed poly(ethylene terephthalate) (PET) and then, ascorbic 
acid were used to reduce silver ions forming silver nanoparticles (NP) [71]. Fourteen-layer 
chitosan Ag NP/heparin multilayer films demonstrated antibacterial features on Escherichia 
coli BL21 strain as the number of bacteria was reduced of 90% after 5 hours, while no 
cytotoxic effect was detected using mouse MC3T3 osteoblast-like cells. 
Recent findings have raised the use of inorganic nanoparticles to impart additional features to 
modulate cell fate [72]. Among others, antioxidant and piezoelectric particles have gained 
interest in the biomedical field for their ability to foster specific cellular behaviour [73]. 
Antioxidant multilayered surfaces have been recently studied for the first time in biomedical 
applications using quercetin as oxidant scavenger [74]. Inorganic nanoparticles based on redox-
reactive metal oxides are an emerging as alternatives to traditional antioxidant agents like 
polyphenols, because inorganic nanoparticles present higher stability in physiological 
environment and longer half-life. In this context, the radical-scavenging role of ceria 
nanoparticles (nanoceria) has been established [75] and LbL assembly has been applied for the 
development of sensors for dopamine detection [76]. Nanoceria nanoparticles were coated with 
polyacrylic-acid (polyacrylic-acid-coated nano-ceria, PNC) and then, multilayers were 
obtained alternating PNC with poly(diallyldimethylammonium chloride) (PDDA). 
Finally, piezoelectric nanoparticles have gained increasing interest as the human bone tissue 
is also a type of piezoelectric material. Many studies have reported the ability of piezoelectric 
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materials to promote bone growth [77]. To date the application of multilayered piezoelectric 
surfaces in the biomedical field has not been reported yet. However, the feasibility of the 
method has been demonstrated by assembling piezoelectric BaTiO3 (BTO) coated with oleic 
acid (OA) and PAA [78], that opens the opportunity to investigate deeply the use of 
piezoelectric materials as polyelectrolyte for the formation of a functional multilayer. Table 1 
summarizes the current use of LbL technologies to add functional moieties to nanostructured 
coatings. 
4. Visionary perspective applications of LbL technology 
In this final section, vision opportunities on different LbL technologies are discussed to 
envisage new frontiers and challenges for the scientific community. Particularly, this section 
describes new LbL strategies for the manufacturing of efficient LbL-coated nanoparticles for 
the treatment of bone cancer, LbL-coated in vitro bone model and LbL-coated films as 
bienzyme sensors for diagnostic and monitoring applications respectively (Figure 7). 
4.1 Spray LbL assembly for the manufacturing of nanoparticles as active defense system 
for treatment of bone cancer 
Bone is the most preferred organ for the formation of metastatic cancer because of its 
microenvironment. Furthermore, cancers, particularly in prostate, breast, kidney and lung, 
have a possible opportunity to be transferred to bone [79]. Currently bone tumor treatments 
mostly include surgical removal of detectable disease followed with chemo- and radio- 
therapies [80]
bone-tumor cells and remaining tumor cells are present around the bone. Moreover, 
conventional radio- and chemo- therapies has been largely used in order to eliminate 
definitely these residual tumor cells, but the related side-effects of these treatments provide 
acute suffering to patients [80, 81]. So far, the important challenge of eliminating residual tumor 
cells as well as repairing bone defects produced by the removal of the malignant bone tumor 
is still open [82]. Thus, it is of unlimited importance to design and manufacture smart 
biomaterials able to kill the remaining bone-tumor cells by using an efficient and secure 
protocol, and, at the same time, to harness the biomaterials bioactivity for improving the 
healing of the bone defect after surgical bone tumor removal. In the last 5 years, an 
extraordinary growth has been noticed in nanomedicine on the production of innovative 
nanoparticles for the diagnosis and treatment of cancer disease. Nanoparticles possess suitable 
biological properties due to their large surface area/volume ratio and small size, enabling to 
absorb, bind and transport several types of substances, ie. drugs, proteins, DNA, RNA, etc. 
with great efficiency [83]. Therefore, their properties allow them to have great stability, carrier 
ability, ability to embed both hydrophobic and hydrophilic compounds, making them 
extremely promising in many features of oncological field [81, 83, 84]. In our opinion, LbL 
assembly can be an extremely useful add-value in order to quickly manufacture multi-
functional NPs in a made-to-order approach [85], allowing as an alternative translation 
approach that can be exploited in industry. Up to date, the main importance has been on the 
use of the LbL coatings as non-degradable membranes for specific deliver of biomolecules 
present in the core, and no attempts have been reported to obtain the ability to target tumors 
within the film structure [86]. NPs have the tendency to accumulate passively in the interstitials 
of the tumor after long circulating, and there is an increasing evidence that the incorporation 
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of targeting moieties enhances the uptake of NP by cancer cells and extends their permanence 
time into the tumor [87]. An interesting approach can be to impart these biological capabilities 
to LbL-coated nanoparticles towards clinical use. The conventional and common strategy to 
achieve tumor selectivity is to coat the nanoparticle surfaces with ligands that can target 
specifically cancer cells [88]. However, this biofunctionaliz -
based chemistry. Therefore, a pH-based approach for cancer targeting can be based on the 
exploitment of the acid pH extracellular micro-environment of tumor colonized bone, that 
approximately is within the range 6.5-7.0 [89]. This pH shift can trigger the LbL multilayer 
disassembly with consequent biomolecules/drugs deliver or to provide and activate specific 
cell-targeting ligands that are not accessible under neutral environments within the 
multilayers [90]. A pioneering work on this topic has been reported by Poon et al [91] where, in 
order to prove a method for achieving the selectivity of tumor cell via LbL coating 
degradation, they manufactured nanoparticles coated, via dipping LbL-assembly, with 
trilayers of poly-L-lysine modified with iminobiotin, followed by the linker protein 
neutravidin and biotin end-functionalised poly(ethylene glycol) (PEG). Their main aim was 
the in vivo targeting of tumor hypoxia. Each materials of the nanocoating was selected 
following a specific rationale: (1) PLL for improving NPs cellular uptake; (2) the affinity 
between iminobiotin and neutravidin is pH-dependent that means stable within the pH range 
8-12 but quickly degraded within the pH range 4-6 due to a less interaction of the protonated 
iminobiotin with the neutravidin [92]; finally (3) PEG as antifouling material that allows the 
coated NPs to avoid fast reticuloendothelial system clearance [93], for improving their 
accumulation in the interstitials of the tumors thanks to enhanced permeation and retention 
effect [94]. The authors demonstrated that this approach may be possibly used to target all 
types of cancer, as well as those that do not express distinct markers at the surface. Different 
polyelectrolytes have been recently investigated, with a more extended stability at neutral 
physiological pH. Indeed Laing et al. designed and manufactured nanoengineered multilayer 
capsules via dipping-LbL assembly, based on the charge-shifting polymer, poly(2-
diisopropylaminoethyl methacrylate) (PDPA), coupled chemically with lauryl methacrylate 
(C12) component. The obtained capsules showed to be stable at pH 7.4, and were activated at 
narrow cellular pH shifts in order to quickly degrade at endosomal pH, enabling to overcome 
the limitation of conjugating small biomolecules/therapeutics to the carrier (that implies 
chemical reaction) without compromising the properties of the biomolecules [95]. Furthermore, 
these capsules showed a controlled release of different hydrophilic molecules with a wide 
molecular weight range (from 500 to 70 kDa). 
Another consideration for the obtainment of active and efficient defense system for bone 
cancer treatment should be done. To the best of our knowledge, up to now few biomaterials 
have been proposed with a double function of tumor therapy and tissue regeneration 
applications respectively. Recently, photothermal therapy (PTT), that consists in a minimally 
invasive and very , showed to improve of tumor 
therapeutics and avoid side effects in several in vivo animal tests [96]. PTT is based on specific 
photo-thermal agents that transform near infrared (NIR) light/irradiation into heat and ablate 
tumor by hyperthermia [97]. Thus, the scientific community may be involved in researches for 
the fabrication of novel bi-functional biomaterials with photothermal therapeutic ability in 
order to treat tumor cells and to repair bone defects derived from surgical resection. In this 
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direction, Cheng et al. [98] proposed a novel PTT system based on poly(3,4 
ethylenedioxythiophene) and poly(4-styrenesulfonate) (PEDOT:PSS), both used as polymeric 
combination in organic electronics field [99] and evidences high absorbance in the near-
infrared region, for extremely in vivo photothermal ablation of tumors in mice. In this work, 
negative-charged PEDOT:PSS nanoparticles were firstly functionalised with positive-charged 
PAH and, after, negative-charge PAA. After the crosslinking of the two layers with the 
amides formation, a branched PEG was conjugated onto the surface of these nanoparticles, for 
improving their stability under physiological conditions [100]. The obtained functionalised 
- characterized by an extremely high tumor 
accumulation because of the cancerous EPR effect. 
Therefore, the strategy to incorporate efficient PTT systems in 3D porous scaffolds has to be 
pursued as reported by Wang et al. [101]. In their work they incorporated molybdenum-based 
(MoS2) nanosheets on the surface of ceramic 3D printed scaffolds, as highly PTT potential. 
They showed that, under NIR, the scaffold temperature quickly increased and efficiently 
controlled by modifying the content of MoS2 nanosheets, as well as scaffold dimensions and 
density of the laser power. Biological studies demonstrated the efficiency of photothermal 
temperature in vitro in decreasing breast cancer and osteosarcoma cells viability, and in vivo 
in the inhibition of the tumor growth. Moreover, the scaffolds allowed the adhesion, 
proliferation and osteogenic MSCs differentiation, inducing in vivo bone regeneration. This 
bi-functional scaffold, able to treat the bone cancer and support the growth of bone, offered an 
encouraging clinical approach for the treatment of bone defects induced by tumor. This proof 
of concept work demonstrated the practicability of the combination of localized therapy for 
tumor with tissue regeneration by using multi-functional and multi-layered materials. 
Compared with the physical absorption of photothermal therapeutics, as reported in the 
ase time rate 
of the therapeutic agents, reducing their content that may be dangerous for the overall 
cytocompatibility of the scaffolds. 
Finally, the use of siRNAs is taking a great attention as targeted therapeutics with the capacity 
for the treatment of tumors that are unaffected by the conventional therapies [102]. Therefore, 
the combination of genetic targeting of specific resistance tumor cell pathways with the 
chemotherapy drugs release can offer the opportunity to swi  the ability of 
tumor cell to fight, with a great efficacy increase of the treatment. But, to make significant 
clinical siRNA therapeutics for treating advanced pathologies, important features should be 
considered: (1) extended permanence of NPs in circulation to permit continuous therapy to 
the tumor cells [102]; (2) effective siRNA embedding into the nanoparticles to avoid losses 
from the low uptake and endosomal escape rates into tumor site [103]; (3) biomaterials should 
control the siRNA endosomal escape avoiding the cytotoxicity [104]. In literature recent works 
reported different biomaterials for the preparation of suitable siRNA-loaded nanoparticles, eg. 
block copolymers [105], copolypeptides [106], cyclodextrins, and charged-lipids, that can 
solidify at 37 C [107]. However, it is challenging to mediate or modify factors for siRNA 
release, eg. siRNA molecules embedded into the nanoparticles and the ratio between siRNA 
and cationic polymer/lipid that may influence dramatically the therapeutic window. Indeed, 
incorporation of the siRNA, where the molar ratio between polycation and siRNA can achieve 
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high values, from 10 to 20:1. These process parameters can increase toxic side effects with a 
consequent decrease of the siRNA amount released systemically [108]. Finally, recent works 
revealed that several siRNA-complexes do not offer a synergic combination of chemotherapy 
drugs with inhibitors: this is a new open challenge that includes chemotherapy loading in a 
modular fashion -coated nanoparticles can offer an exciting 
siRNA- delivery systems with interesting clinically translational potential. Few researchers 
have described the procedures to incorporate siRNA molecules into the superficial coated 
layers of nanoparticles [62, 109]. Recently, Deng et al. reported a novel co-delivery system, to 
target a strong aggressive breast cancer form, made of multilayered coating on the 
chemotherapy drug-loaded NPs surface (via alternative deposition of siRNA and poly-L-
arginine as bilayer with the possibility to actually incorporate up to 3500 siRNA molecules), 
as shown in Figure 7, followed by additional functionalisation of an outer coating for tumor-
targeting and properties [109]. Up to date, no studies on the effect of siRNA release 
from LbL-coated NPs on bone cancer are present in literature; thus it still remains an open 
challenge to be deeply investigated. 
Finally, an ultimate consideration can be done on the manufacturing of the LbL-coated NPs 
that have been largely mentioned in the previous paragraphs. Although all these researches 
used the conventional dipping LbL assembly for the NPs manufacturing, the alternative spray 
LbL assembly can be strongly considered because it is much faster than immersive assembly, 
and the length of cycle for adsorption is reduced to a few seconds (~6 s per layer) in 
comparison to the immersive coating that requires an average of 15 min per layer [110]. In 
addition, another important advantage of the spray-based system is related to the possibility of 
recycling the solution in the original reservoirs [111]. In the case of drug incorporation, the 
spray LbL enables the build-up of nanocoatings with a greater system efficiency, since it 
contributes to maximize the drug loading, preventing the diffusion within the dipping bath 
[112]. 
The ease of the spray-assembly method, combined with the rapid process times along with the 
increased efficiency observed offer great promise for the translation of this technology from 
the laboratory scale to industrial level mass production. 
4.2 Dipping LbL assembly for nanocoated cellular systems for cell-based therapy 
Cell encapsulation using the LbL deposition method implies the coating of a multilayered 
films on single cells or cell aggregates surfaces [113] (Figure 7). This LbL strategy has 
impressive potentiality for proposing new solutions for bone regeneration. However, 
differently with the resilient and thick microbial cells lipid bilayer, cells from animals do not 
have the polysaccharide-reinforced cell wall that allows them to be disposed to mechanical 
stresses and osmotic pressure. Thus, a deep biomaterials selection for coating animal cells is 
essential [114]. Moreover, the cell surface exposure to a positive-charged layer may lead to the 
disruption of the cell membrane, causing apoptosis. However, due to the fact the cells are 
exposed minimally to the polycations toxicity and due to the high permeability of cell 
capsules, hydrogen bonding-based LbL coatings evidenced higher cell viability (~80%) when 
compared with the ionically-based layers (<25%) [115]. 
Multilayered coating of single cells has been used to define appropriate microenvironments to 
regulate cell behaviour (eg. adhesion, proliferation and differentiation) by, as example, the 
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addition of osteoinductive biomolecules in the multilayer, such as specific growth factors, 
peptide sequences, etc. Bone morphogenetic proteins (BMPs) can be added into the cell 
coating in order to be delivered according specific times and pH, thus improving the 
regulation of MSCs [-differentiation in osteoblasts. The use of natural polymer-based 
polyelectrolytes (eg. gelatin, chitosan) are required in order to have a cytocompatible coating 
that not affect significantly the MSCs viability, as proposed for other applications involving 
neural stem cells [116]. 
Another challenging target can be represented by LbL deposition of multilayers for coating 
transplanted allogenic cells, to avoid immune rejection. The reaction of immune system is a 
frequent problem for using biomaterials in order to regeneration all tissues. Particularly, cells 
transplantation, scaffolds implant, or biomolecules deliver can lead this immune response. 
Although the immune reaction realizes several necessary tasks, eg. removal of cellular debris 
due to injuries and reducing infection, the early inflammatory response can cause further 
damage to the tissue [117], that can compromise the healing. Therefore, it is fundamental to not 
prevent completely the macrophages infiltration because it can stimulate more wide tissue 
damage combined with regeneration ability decrease [118]. Preliminary experiments have been 
performed on human cartilage cells encapsulation within LbL coating of sodium cellulose 
sulfate (as polyanion) and poly-diallyl(dimethyl-ammoniumchloride) (as polycation) where an 
efficient immunoprotection in vivo has been proved [119]. 
4.3 Fluidic LbL assembly for the obtainment of in vitro bone model 
Further application of LbL assembly can include the manufacturing of microfluidic devices, 
called organs-on-chips that have been designed and created to mimic tissues/organs in order 
to simulate the physiological cellular micro-environment. Recent findings on these 
microfluidic models have started to recreate in vitro pathological states in order to improve 
the knowledge on the biological processes as well as for drug screening. These microfluidic 
systems show great potential for pharmaceutical, biomedical and toxicological fields [120]. 
Moreover, in vitro models have the potential to offer an ethical approach with improved 
scientific accuracy that is more appropriate from both an animal welfare and scientific view. 
Recently researchers are concentrating their attention on the in vitro manufacturing of bone 
tissues for mimicking functional properties of natural bone, such as microarchitecture and 
mechanical strength. One of the big challenges is due to the fact that, although cancellous and 
cortical bone are structural different, they both include a vascularised network, fundamental to 
nutrient flow and waste removal. Thus, microvascular systems can be designed and 
manufactured as 3D in vitro models for evaluating biological processes in living systems. 
Particularly, up to date, microfluidic devices have been developed for vascularized bone 
tissue models to investigate breast cancer metastasis to the bone and cancer extravasation via 
simulating an osteo-cell condition micro-environment [121]. Moreover, platforms of 
vascularised in vitro bone model are under investigation in order to evaluate angiogenic 
potential [122], as well as in combination of osteogenesis [123], because bone angiogenesis has 
significant part in bone tissue formation and regeneration. However, these traditional or 
microfluidic in vitro models were not able to simulate the bone angiogenesis in vivo that is 
characterized by the growth of the vessels within the mineralised bone Extracellular Matrix 
(ECM) [124]. Furthermore, a suitable platform for manufacturing in vitro bone tissue should 
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possess 3D structures with interconnected pores as well as appropriate mechanical properties 
to support the cell activities, such as adhesion, proliferation, and differentiation. Thus, a 
further manufacturing approach can combine the layer-by-layer assembly deposition with the 
3D printing in order to model vascularised bone for creating porous and channeled structures 
and biomolecules gradients. 
As example, the biological environments able to support the viability and spreading of cells 
(osteoblasts and osteocytes) or to block their migration can be studied in terms of 
multilayered coating stiffness with or without the incorporation of specific short peptide 
sequences like RGD ligand. Moreover, the influence of VEFGs in combination with mono-, 
co-, and tri-cultures on the formation of capillary like network in 3D can be an surplus 
investigation in order to offer evidence on the influence of the different component on the 
angiogenesis [125]. Among all the different LbL technologies, the fluidic assembly has the 
suitable characteristics to coat, with or without biomolecules incorporation, channel walls and 
substrates placed or immobilized in a 3D printed microfluidic device. This LbL technology is 
usually applied by a capillary force, pump, or spinning in order to allow the liquid flow 
through the channels. Furthermore, in literature specific perfusion chambers are described for 
fluidic layering of complex 3D structures, ie. sensitive biological substrates, that can continue 
to be constantly hydrated during the coating [126]. 
4.4 Electromagnetic LbL assembly applied for bienzyme sensors 
Bone is a very dynamic tissue with the ability of constant remodeling all over adult life. 
Currently, the gold standard to evaluate bone remodeling and mineral density has defined 
limits, novel methods are being developed [127]. Enzyme-linked immunosorbent assays 
(ELISAs), that assess amounts on picogram scale, are usually used for measuring specific 
bone turnover markers (BTMs)[128]. Among others, two formation markers (serum bone-
specific alkaline phosphatase (s-BALP) and serum procollagen type I N-terminal propeptide 
(s-PINP)) and two bone resorption markers (urine N-terminal telopeptide of type I collagen 
(u-NTX) and serum C-terminal telopeptide of type I collagen (s-ßCTX)) are the most 
commonly used in clinics to monitor osteoporosis[129]. This evaluation is of great significance 
for clinicians in order to monitor the fractured bone biomechanics and its remodeling process 
for selecting the suitable treatment to reduce complications and improve the quality of life of 
the patient [130]. However, these ELISA assays are very expensive in terms of high material 
costs, and require long period of incubation and particular equipment, which need clinical 
labelling [130]. Another method for controlling the healing of bone fracture is based on difficult 
imaging technologies that not allow to observe the patient during outpatient visits or 
physiotherapy [131]. Therefore, due to the above mentioned limitations, there is an increasing 
request to manufacture different biosensors to offer low-cost miniaturized platforms to 
evaluate more precisely bone remodeling process. 
In order to offer accurate, quick, easy, point-of-care assessment of biomarkers, electric field- 
induced LbL can be an interesting option for the manufacturing of biosensors for the detection 
ve biomarker detection. This specific LbL technology has already been 
explored in biomedical application for the preparation of biocompatible nanocoatings, which 
negligible cytotoxicity has been reported by Wang et al [33] through in vitro biological tests. 
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Particularly, in this work chitosan and alginate were used as polyelectrolytes to coat Ti-based 
substrates. During the electrodeposition process at constant voltage of 20 V, the titanium plate 
was the anode to deposit the initial alginate-based layer combined with a parallel platinum 
plate as counterelectrode. After drying, a second chitosan-based layer was deposited but using 
the previous titanium plate as cathode and the parallel platinum plate as counterelectrode. 
This procedure was repeated several times in order to create a stable nanocoating. Compared 
with the traditional bienzyme assays, electromagnetic LbL gives the opportunity to prepare 
bienzyme coatings with bioelectric catalytic functions characterized by high surface coverage 
and, thus, activity, decreasing the correlated costs through the use of available commercial 
sensors, and may utilize easy assays that do not involve any labelling variation. A pioneering 
study on the use of electromagnetic LbL assembly for bienzyme sensors manufacturing is 
reported by Shi et al. [132]. They proposed a multilayered film based on enzyme and 
polyelectrolyte on a transparent indium-tin oxide covered glass electrode surface, where two 
different enzymes were distributed homogenously laterally on the same substrate without 
interfering. Particularly, electromagnetic LbL assembly was used to deposit alternatively 
different redox enzymes (glucose oxidase and catalase) and PDDA. The authors demonstrated 
that was the possibility to regulate correctly the enzyme activity and spatial arrangement, 
enabling to build multilayered bienzyme sensors as desired. Therefore, electromagnetic LbL 
assembly can open the field for a next generation of biomechanical multi-enzyme systems 
with strong evidenced on the quality of live bone. 
5. Conclusions 
As J Richardson et al said overall, the future of LbL assembly is bright, and as the black box 
of assembly technologies is slowly illuminated, great potential for innovation and application 
will be found [7]. Layer-by-layer assembly is a consolidated technology and presents an 
unlimited potential to be used in diverse and multiple fields. Although several new 
approaches and developments have been proposed for the treatment of bone-related diseases 
and regeneration, unmet challenges are still present. Actually, there is a need for faster and 
more stable coatings to enable long term storage of multilayer systems and manufacturing of 
innovative and efficient bone medical devices at low costs and high reproducibility. On this 
regard, the combination of LbL method with nano-drug delivery technology can offer a fully 
integrated approach to treat other bone disorders, e.g. osteoporosis, osteomalacia, etc. LbL 
assembly-based methods, integrated with other fabrication technologies (e.g. additive 
manufacturing), can significantly lead to revolutionary and novel developments (unique 
multilayer properties or accelerated deposition processes) in order to overcome the remaining 
challenges of the industrial manufacturing scale-up. Finally, progresses in LbL technology is 
happening quicker than ever, mainly in biomedicine field, and it is expected that new LbL 
assembly-based methods subcategories will be complemented to increase past conventional, 
non-conventional and quasi-LbL assembly. 
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Figures 
 
 
 
Figure 1. Layer-by-layer assembly technologies. (A to E) Schematics of the five major 
technology categories for LbL assembly. Reproduced with permission [7] 2015 The American 
Association for the Advancement of Science. 
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Figure 2. Last five years of LbL assembly applied to bone tissue field: cumulative number of 
-by- -by-layer bone 
-by- -by-
since 2014. This timeline is intended to highlight the general trends of LbL assembly in bone 
applications and is not exhaustive. Search performed in ISI Web of Knowledge database on 
July 11, 2018. 
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A
B
 
 
Figure 3. (A) 
SEM images of a pure SF scaffold and b, c, d SF/CNW CS 
composite scaffold with 32, 54, 108 assemble layers, respectively. Reproduced with 
permission[31] 2016, Springer. 
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Figure 4. SEM micrographs of native PEEK (A, B), and LbL treated PEEK after 5 layers (C, 
D), 10 layers (E, F) and 20 layers (G, H). Reproduced with permission [38] 2017, Elsevier. 
 
 
 
Figure 5. Process for LbL-coated nanoparticles (NPs). NPs were iteratively coated with 
anionic polyelectrolyte (PAA) and polycationic poly- L lysine (PLL). PAA was 
functionalized with the bisphosphonate targeting moiety to boost the NPs affinity to bone 
cells. Reproduced with permission[55] 2013, Wiley-BCH. 
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A B
 
Figure 6. Schematic representation of two approaches to produce a biomimetic organic-
inorganic biocomposites through LbL methodology. (A) Composite multi-layered coating on 
Ti substrate obtained by alternative assembly of dopamine and HAP where a polydopamine 
layer (PDPOA) was obtained in slightly alkaline environment and then immersed into SBF 
solution to achieve HAP precipitation; the process was repeated nine times to obtain nine bi-
layers. (B) Spiral shaped PLGA-based construct coated with alternate layers of cationic 
chitosan (in red) and anionic HAP (in blue) to mimic both the composition and the structures 
of bone tissue. Adapted with permission from [66] 2014, RSC and from [68] 2018, ACS 
Publications. 
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